Zentalis Pharmaceuticals, Inc. (ZNTL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Zentalis Pharmaceuticals, Inc. (ZNTL) trades at $4.87 with AI Score 27/100 (Grade F). Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for various cancers. Market cap: $346.68M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026ZNTL stock analysis for 2026: Analysts have set a consensus price target of $5.31 for Zentalis Pharmaceuticals, Inc., suggesting 9.1% upside from the current price of $4.87. The AI MoonshotScore is 27/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ZNTL: 4/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Zentalis Pharmaceuticals, Inc. (ZNTL) Healthcare & Pipeline Overview
Zentalis Pharmaceuticals, Inc. (ZNTL) is a clinical-stage biopharmaceutical company specializing in small molecule therapeutics for cancer treatment. Their pipeline includes WEE1 inhibitors, selective estrogen receptor degraders, and BCL-2 inhibitors, positioning them in the competitive oncology drug development landscape with a focus on precision medicine.
What Is the Investment Thesis for ZNTL?
Zentalis Pharmaceuticals presents a notable research candidate within the biotechnology sector, driven by its diverse pipeline of small molecule therapeutics targeting various cancers. The company's lead candidate, ZN-c3, a WEE1 inhibitor in Phase 2 trials, and ZN-c5, an oral SERD in Phase 1/2 trials, represent significant potential value drivers. Successful clinical trial outcomes and potential regulatory approvals for these candidates could lead to substantial revenue growth. The company's strategic collaborations with major pharmaceutical companies like Pfizer and GSK further validate its technology and provide financial resources for continued development. However, the inherent risks associated with clinical-stage drug development, including trial failures and regulatory hurdles, must be considered. As of 2026-05-09, Zentalis has a market capitalization of $346.68M, reflecting both the potential and the risks associated with its pipeline.
Based on FMP financials and quantitative analysis
ZNTL Key Highlights
- Lead product candidate ZN-c3 is in Phase 2 clinical trials for advanced solid tumors, targeting the WEE1 protein tyrosine kinase.
- ZN-c5, an oral selective estrogen receptor degrader, is in Phase 1/2 clinical trials for advanced estrogen receptor-positive breast cancer.
- Developing ZN-d5, a selective inhibitor of B-cell lymphoma 2, currently in Phase 1 clinical trial for non-Hodgkin's lymphoma and acute myelogenous leukemia.
- Developing ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in Phase 1/2 clinical trial for advanced non-small cell lung cancer.
- Strategic collaborations with major pharmaceutical companies like Pfizer and GSK provide financial support and validation of their technology.
Who Are ZNTL's Competitors?
ZNTL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARRY Array Technologies, Inc. | $6.94 | -0.37% | $1.07B | — |
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| GSK GSK plc | $53.20 | -0.87% | $106.54B | 61 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZNTL's Key Strengths?
- Diverse pipeline of small molecule therapeutics.
- Strategic collaborations with major pharmaceutical companies.
- Proprietary drug discovery platform.
- Experienced management team.
What Are ZNTL's Weaknesses?
- Clinical-stage company with no approved products.
- High cash burn rate due to R&D expenses.
- Reliance on clinical trial success.
- Limited commercialization capabilities.
What Could Drive ZNTL Stock Higher?
- Phase 2 clinical trial results for ZN-c3 in advanced solid tumors.
- Phase 1/2 clinical trial results for ZN-c5 in advanced breast cancer.
- Enrollment and data readout from Phase 1 clinical trial for ZN-d5 in non-Hodgkin's lymphoma and acute myelogenous leukemia.
- Advancement of ZN-e4 through Phase 1/2 clinical trial for advanced non-small cell lung cancer.
What Are the Key Risks for ZNTL?
- Financial-distress signal — its Altman Z-Score of -4.93 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-53.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for lead drug candidates.
- Regulatory delays or non-approval of drug candidates.
- Competition from other pharmaceutical companies in the oncology market.
- High cash burn rate and need for additional financing.
- Patent challenges or loss of exclusivity.
What Are the Growth Opportunities for ZNTL?
- Expansion of ZN-c3 into New Tumor Types: Zentalis has the opportunity to expand the clinical development of ZN-c3, its WEE1 inhibitor, into additional tumor types beyond advanced solid tumors. Given the role of WEE1 in DNA damage response and cell cycle regulation, ZN-c3 could potentially be effective in a range of cancers with specific genetic mutations or vulnerabilities. This expansion could significantly increase the addressable market for ZN-c3 and drive revenue growth, with potential market size reaching billions of dollars over the next 3-5 years.
- Advancement of ZN-c5 in Breast Cancer Treatment: Zentalis can capitalize on the growing need for effective treatments for advanced estrogen receptor-positive breast cancer by advancing ZN-c5, its oral selective estrogen receptor degrader (SERD), through clinical development. The SERD market is projected to grow significantly as resistance to existing therapies increases. Successful clinical trial outcomes and regulatory approval for ZN-c5 could position Zentalis as a key player in the breast cancer treatment landscape, with potential peak sales in the hundreds of millions of dollars within 5-7 years.
- Development of BCL-2 Inhibitor ZN-d5 for Hematological Malignancies: Zentalis has the opportunity to develop ZN-d5, its selective BCL-2 inhibitor, for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia. BCL-2 inhibitors have shown promise in treating these hematological malignancies, and ZN-d5 could offer advantages over existing therapies. Successful clinical development and regulatory approval could lead to significant market share in the hematological oncology space, with potential revenue generation within the next 4-6 years.
- Exploiting Strategic Collaborations for Pipeline Expansion: Zentalis can leverage its existing strategic collaborations with companies like Pfizer and GSK to expand its therapeutic pipeline and accelerate drug development. These collaborations provide access to resources, expertise, and potential co-development opportunities. By actively pursuing new partnerships and expanding existing ones, Zentalis can diversify its pipeline and mitigate the risks associated with relying on a limited number of drug candidates. This collaborative approach could lead to the identification and development of new drug candidates within the next 2-3 years.
- Expansion into New Therapeutic Areas Beyond Oncology: While Zentalis is currently focused on oncology, the company has the potential to expand into new therapeutic areas beyond cancer. The company's expertise in small molecule drug discovery and development could be applied to other diseases with unmet medical needs. By diversifying its therapeutic focus, Zentalis can reduce its reliance on the oncology market and create new growth opportunities. This expansion could involve licensing new drug candidates or developing its own internal programs in areas such as immunology or neurology, with potential impact within 5-7 years.
What Opportunities Does ZNTL Have?
- Expansion of existing drug candidates into new indications.
- Acquisition or in-licensing of new drug candidates.
- Further strategic collaborations with pharmaceutical companies.
- Potential for accelerated regulatory approval pathways.
What Threats Does ZNTL Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other pharmaceutical companies.
- Patent expirations and generic competition.
What Are ZNTL's Competitive Advantages?
- Proprietary small molecule drug discovery platform.
- Strong intellectual property portfolio protecting its drug candidates.
- Strategic collaborations with major pharmaceutical companies.
- Experienced management team with expertise in drug development and commercialization.
What Does ZNTL Do?
Zentalis Pharmaceuticals, Inc., founded in 2014 and based in New York City, is dedicated to discovering and developing innovative small molecule therapeutics for the treatment of various cancers. The company's approach centers on targeting fundamental biological pathways that drive cancer growth and resistance. Their lead product candidate, ZN-c3, a WEE1 inhibitor, is currently in Phase 2 clinical trials for advanced solid tumors. Additionally, Zentalis is developing ZN-c5, an oral selective estrogen receptor degrader (SERD), in Phase 1/2 clinical trials for advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Beyond these lead programs, Zentalis is also advancing ZN-d5, a selective BCL-2 inhibitor, in a Phase 1 clinical trial for non-Hodgkin's lymphoma and acute myelogenous leukemia, and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor (EGFR), in a Phase 1/2 clinical trial for advanced non-small cell lung cancer (NSCLC). The company is also developing BCL-xL heterobifunctional degraders. Zentalis has established strategic collaborations and licensing agreements with several organizations, including Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd., to support its research and development efforts and expand its therapeutic pipeline. Zentalis focuses on precision medicine, aiming to develop targeted therapies that address specific genetic and molecular drivers of cancer.
What Products and Services Does ZNTL Offer?
- Discovers and develops small molecule therapeutics.
- Focuses on treatments for various cancers.
- Develops WEE1 inhibitors for advanced solid tumors.
- Creates oral selective estrogen receptor degraders (SERDs) for breast cancer.
- Develops BCL-2 inhibitors for non-Hodgkin's lymphoma and acute myelogenous leukemia.
- Develops mutant epidermal growth factor receptor (EGFR) inhibitors for non-small cell lung cancer.
- Engages in strategic collaborations with pharmaceutical companies.
How Does ZNTL Make Money?
- Develops and patents novel small molecule therapeutics.
- Conducts preclinical and clinical trials to evaluate drug efficacy and safety.
- Out-licenses or co-develops drug candidates with pharmaceutical partners.
- Seeks regulatory approval from agencies like the FDA.
- Commercializes approved drugs directly or through partners.
What Industry Does ZNTL Operate In?
Zentalis Pharmaceuticals operates within the highly competitive biotechnology industry, which is characterized by rapid innovation, stringent regulatory requirements, and high levels of investment in research and development. The oncology therapeutics market is a significant segment within the biotechnology industry, driven by the increasing prevalence of cancer and the demand for more effective and targeted treatments. Zentalis's focus on small molecule therapeutics and precision medicine aligns with current industry trends towards personalized cancer therapies. The company faces competition from both established pharmaceutical companies and other emerging biotech firms, all vying for market share in this dynamic and rapidly evolving landscape.
Who Are ZNTL's Key Customers?
- Patients with various types of cancer.
- Oncologists and other healthcare professionals who prescribe cancer treatments.
- Pharmaceutical companies that partner with Zentalis for drug development and commercialization.
- Hospitals and cancer centers that administer cancer treatments.
FY2026 estForward Outlook
Wall Street analysts project Zentalis Pharmaceuticals, Inc. revenue of about $2.1M for fiscal 2026, with EPS near $-1.94. The estimate reflects 8 contributing analysts.
F-Score 1/9Financial Health
Zentalis Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.93 places it in the distress zone, a signal of elevated financial risk.
ROE -54%Key Financial Metrics
Return on equity for Zentalis Pharmaceuticals, Inc. stands at -53.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -49.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -39.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -39.6%, the inverse of the P/E and a quick read on earnings relative to price.
Zentalis Pharmaceuticals, Inc. (ZNTL) Valuation Context
Valued at $346.68M, ZNTL is classified as a small-cap stock. Relative to its peer group, ZNTL's quantitative score of 27/100 is below the peer average of 79/100.
Company Profile
Zentalis Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Julie Eastland. ZNTL has traded publicly since 2020.
ZNTL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates strong confidence in Zentalis' future, suggesting executives believe in the company's potential.
- Community sentiment has turned positive as recent trial results for their lead drug have shown promise, boosting investor enthusiasm.
- Analysts have noted a growing interest in Zentalis' innovative approach to cancer therapies, which could position them favorably in a competitive market.
- Partnerships with established pharmaceutical companies have been highlighted, suggesting validation of their research and development efforts.
Bear Case
- Concerns over regulatory hurdles for new drug approvals have surfaced, creating uncertainty among investors about timelines.
- Recent community discussions have shown skepticism regarding the scalability of Zentalis' therapies, with some doubting their market viability.
- Market perception has been cautious due to broader economic factors, leading to hesitance in investing in biotech stocks like Zentalis.
- Insider selling activity has raised eyebrows, suggesting that some executives may be cashing out, which could indicate a lack of confidence in the near-term outlook.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ZNTL Latest News
-
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com · May 13, 2026
-
Zentalis Pharma Q1 EPS $(0.50) Misses $(0.47) Estimate
benzinga · May 12, 2026
-
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
globenewswire.com · May 12, 2026
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · May 11, 2022
ZNTL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZNTL.
Price Targets
Consensus target: $5.31
ZNTL MoonshotScore
What does this score mean?
The MoonshotScore rates ZNTL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharma Q1 EPS $(0.50) Misses $(0.47) Estimate
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
Stocks That Hit 52-Week Lows On Wednesday
Latest Zentalis Pharmaceuticals, Inc. Analysis
Leadership: Julie Eastland
Chief Executive Officer
Julie Eastland serves as the Chief Executive Officer of Zentalis Pharmaceuticals, bringing extensive experience in the biopharmaceutical industry. Her background includes leadership roles in various pharmaceutical companies, where she focused on strategic planning, business development, and commercial operations. She has a proven track record of driving growth and innovation in the healthcare sector. Her expertise spans across multiple therapeutic areas, including oncology, and she has been instrumental in the development and launch of several successful pharmaceutical products.
Track Record: Under Julie Eastland's leadership, Zentalis Pharmaceuticals has advanced its pipeline of small molecule therapeutics, with several drug candidates progressing through clinical trials. She has overseen strategic collaborations with major pharmaceutical companies, securing funding and resources for continued development. Her focus on innovation and strategic partnerships has positioned Zentalis as a key player in the oncology drug development landscape.
Common Questions About ZNTL (Healthcare)
What does Zentalis Pharmaceuticals, Inc. do?
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for the treatment of various cancers. The company's pipeline includes drug candidates targeting critical cancer pathways, such as WEE1, estrogen receptors, BCL-2, and EGFR. These candidates are currently in various stages of clinical development, with the goal of providing new and effective treatment options for patients with cancer. Zentalis operates through strategic collaborations and internal research and development efforts.
What do analysts say about ZNTL stock?
Analyst coverage of Zentalis Pharmaceuticals (ZNTL) typically focuses on the company's clinical trial progress, regulatory milestones, and potential market opportunities for its drug candidates. Valuations are often based on discounted cash flow models, considering the probability of success for each drug in the pipeline. Analyst consensus may vary depending on individual assessments of clinical data and market potential. Investors should conduct their own due diligence and consider multiple sources of information before making investment decisions.
What are the main risks for ZNTL?
The main risks for Zentalis Pharmaceuticals include the inherent uncertainties associated with clinical-stage drug development. Clinical trial failures, regulatory delays, and competition from other pharmaceutical companies pose significant challenges. The company's high cash burn rate and need for additional financing also represent financial risks. Additionally, patent challenges or loss of exclusivity could impact the company's long-term revenue potential. Investors should carefully consider these risks before investing in ZNTL.
What are the key factors to evaluate for ZNTL?
Zentalis Pharmaceuticals, Inc. (ZNTL) holds an AI score of 27/100 (low). Analysts target $5.31 (+9%). Not financial advice.
How frequently does ZNTL data refresh on this page?
ZNTL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ZNTL's recent stock price performance?
Zentalis Pharmaceuticals, Inc. (ZNTL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse pipeline of small molecule therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZNTL overvalued or undervalued right now?
Valuing Zentalis Pharmaceuticals, Inc. (ZNTL) requires multiple metrics. Analysts target $5.31 (+9%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ZNTL?
Before investing in Zentalis Pharmaceuticals, Inc. (ZNTL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-09 and is subject to change.
- Clinical trial outcomes are inherently uncertain and may impact future results.